Literature DB >> 15619391

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure.

Stuart D Katz1, John D Parker, Dale B Glasser, Alan J Bank, Nancy Sherman, Hao Wang, Michael Sweeney.   

Abstract

Chronic heart failure (CHF) is an increasingly common cardiovascular disorder. Many patients who have CHF report moderate to marked decreases in the frequency of sexual activity, and up to 75% of patients report erectile dysfunction (ED). There are few controlled clinical data on the efficacy and safety of sildenafil citrate in men who have ED and CHF; thus, we evaluated these parameters in patients who had stable CHF. This was a double-blind, placebo-controlled, flexible-dose study. Men who had ED and stable CHF were randomized to receive sildenafil or placebo for 12 weeks. Primary outcomes were questions 3 and 4 of the International Index of Erectile Function. Secondary outcomes included the 5 functional domains of the International Index of Erectile Function, 2 global efficacy assessment questions, intercourse success rate, the Erectile Dysfunction Inventory of Treatment Satisfaction, and the Life Satisfaction Checklist. By week 12, patients who received sildenafil (n = 60) showed significant improvements on questions 3 and 4 compared with patients who received placebo (n = 72; p <0.002). Larger percentages of patients who received sildenafil reported improved erections (74%) and improved intercourse (68%) compared with patients who received placebo (18% and 16%, respectively). Intercourse success rates were 53% among patients who received sildenafil and 20% among those who received placebo. Patients who received sildenafil were highly satisfied with treatment and their sexual life compared with patients who received placebo. Sixty percent of patients who received sildenafil and 48% of patients who received placebo developed adverse events, including transient headache, facial flushing, respiratory tract infection, and asthenia. The incidence of events related to cardiovascular effects was low. Sildenafil is an effective and well-tolerated management of ED in men who have mild to moderate CHF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15619391     DOI: 10.1016/j.amjcard.2004.08.060

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Effect of cardiac resynchronization therapy on libido and erectile dysfunction.

Authors:  Ahmet Vural; Aysen Agacdiken; Umut Celikyurt; Melih Culha; Goksel Kahraman; Guliz Kozdag; Dilek Ural
Journal:  Clin Cardiol       Date:  2011-06-02       Impact factor: 2.882

Review 2.  The emerging role for type 5 phosphodiesterase inhibition in heart failure.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2006-09

Review 3.  Erectile dysfunction as a complication of heart failure.

Authors:  Afshan Baraghoush; Anita Phan; Robert D Willix; Ernst R Schwarz
Journal:  Curr Heart Fail Rep       Date:  2010-12

Review 4.  Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

Authors:  Gautam V Ramani; Myung H Park
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

Review 5.  Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.

Authors:  Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Barry A Borlaug; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-05       Impact factor: 8.790

Review 6.  Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure.

Authors:  Steve Tsai; Marc Klapholz
Journal:  Curr Heart Fail Rep       Date:  2007-06

Review 7.  Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.

Authors:  In-Chang Hwang; Yong-Jin Kim; Jun-Bean Park; Yeonyee E Yoon; Seung-Pyo Lee; Hyung-Kwan Kim; Goo-Yeong Cho; Dae-Won Sohn
Journal:  BMC Cardiovasc Disord       Date:  2017-06-12       Impact factor: 2.298

Review 8.  Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

Authors:  F Giuliano; G Jackson; F Montorsi; A Martin-Morales; P Raillard
Journal:  Int J Clin Pract       Date:  2009-11-09       Impact factor: 2.503

Review 9.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

10.  Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.

Authors:  Renato De Vecchis; Arturo Cesaro; Carmelina Ariano
Journal:  Interv Med Appl Sci       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.